MX2016012784A - Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. - Google Patents

Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.

Info

Publication number
MX2016012784A
MX2016012784A MX2016012784A MX2016012784A MX2016012784A MX 2016012784 A MX2016012784 A MX 2016012784A MX 2016012784 A MX2016012784 A MX 2016012784A MX 2016012784 A MX2016012784 A MX 2016012784A MX 2016012784 A MX2016012784 A MX 2016012784A
Authority
MX
Mexico
Prior art keywords
compositions
solid pharmaceutical
pharmaceutical compositions
biopterin derivatives
biopterin
Prior art date
Application number
MX2016012784A
Other languages
English (en)
Inventor
Frank Tegtmeier
Scheurer Peter
Schinzel Reinhard
Original Assignee
Vasopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Gmbh filed Critical Vasopharm Gmbh
Publication of MX2016012784A publication Critical patent/MX2016012784A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas sólidas que comprenden derivados de biopterina, así como también, a métodos para obtener dichas composiciones farmacéuticas sólidas. La invención también se refiere a las composiciones farmacéuticas sólidas de la invención para tratar enfermedades.
MX2016012784A 2014-03-31 2015-03-30 Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. MX2016012784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PCT/EP2015/056824 WO2015150294A1 (en) 2014-03-31 2015-03-30 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Publications (1)

Publication Number Publication Date
MX2016012784A true MX2016012784A (es) 2017-04-25

Family

ID=50389975

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012784A MX2016012784A (es) 2014-03-31 2015-03-30 Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.

Country Status (29)

Country Link
US (6) US9895372B2 (es)
EP (2) EP2926805B1 (es)
JP (3) JP6552515B2 (es)
KR (1) KR102374500B1 (es)
CN (2) CN106572976A (es)
AU (2) AU2015239736B2 (es)
CA (1) CA2938267C (es)
CL (1) CL2016002463A1 (es)
CY (1) CY1117881T1 (es)
DK (1) DK2926805T3 (es)
ES (1) ES2586945T3 (es)
HK (1) HK1213195A1 (es)
HR (1) HRP20160802T1 (es)
HU (1) HUE030221T2 (es)
IL (1) IL248090B (es)
MX (1) MX2016012784A (es)
MY (1) MY180844A (es)
PE (1) PE20161253A1 (es)
PH (1) PH12016501519A1 (es)
PL (1) PL2926805T3 (es)
PT (1) PT2926805T (es)
RS (1) RS54973B1 (es)
RU (1) RU2694368C2 (es)
SA (1) SA516371933B1 (es)
SG (1) SG11201606151SA (es)
SI (1) SI2926805T1 (es)
SM (1) SMT201600246B (es)
WO (1) WO2015150294A1 (es)
ZA (1) ZA201605271B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2926805T3 (en) * 2014-03-31 2016-07-25 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterine derivatives and uses of such compositions
JP2016168783A (ja) * 2015-03-13 2016-09-23 株式会社東芝 記録装置、記録方法、及び記録媒体
EP3675863A4 (en) * 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. PHARMACEUTICAL COMPOSITION CONSISTING OF SEPIAPTERIN AND ITS USES
JP6565103B2 (ja) * 2017-09-06 2019-08-28 株式会社昭和冷凍プラント 香気成分含有水溶液を含む液状製品の製造方法
EP4034122A1 (en) * 2019-09-25 2022-08-03 PTC Therapeutics MP, Inc. Methods for treating hyperphenylalaninemia
CA3235704A1 (en) 2021-12-03 2023-06-08 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
TW202406555A (zh) 2022-05-06 2024-02-16 德商ｖｅｒｉＮＯＳ運營有限公司 治療患有與增加的麩胺酸水平相關的疾病狀況或病症的患者的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
DE59703603D1 (de) 1997-10-06 2001-06-28 Ernst Werner Pteridinderivate als NO Synthase-Hemmer
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
CN1894251B (zh) * 2003-11-17 2011-06-29 默克和西伊公司 (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
JP4964587B2 (ja) * 2004-05-11 2012-07-04 第一三共株式会社 Ｂｈ４反応性高フェニルアラニン血症治療剤
SE0401826D0 (sv) 2004-07-09 2004-07-09 Trimble Ab Method of preparing a winding for an n-phase motor
EP2436379A1 (en) * 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
EP1669355A1 (en) * 2004-12-02 2006-06-14 Vasopharm Biotech GmbH Aminotetrahydropteridines and processes for manufacture thereof
JP2010523708A (ja) * 2007-04-11 2010-07-15 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
EP2140731A2 (de) 2007-04-24 2010-01-06 Osram Gesellschaft mit Beschränkter Haftung Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
WO2013033194A1 (en) * 2011-08-30 2013-03-07 Fresenius Kabi Usa, Llc Levothyroxine formulations
DK2926805T3 (en) * 2014-03-31 2016-07-25 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterine derivatives and uses of such compositions

Also Published As

Publication number Publication date
AU2020203880A1 (en) 2020-07-02
EP2926805A1 (en) 2015-10-07
AU2020203880B2 (en) 2022-03-31
WO2015150294A1 (en) 2015-10-08
AU2015239736B2 (en) 2020-03-26
US20200046710A1 (en) 2020-02-13
US11717522B2 (en) 2023-08-08
JP6879582B2 (ja) 2021-06-02
IL248090A0 (en) 2016-11-30
RU2694368C2 (ru) 2019-07-12
JP2017509623A (ja) 2017-04-06
US10493075B2 (en) 2019-12-03
RU2016141449A (ru) 2018-05-07
CA2938267C (en) 2023-05-09
PT2926805T (pt) 2016-07-15
SG11201606151SA (en) 2016-08-30
NZ722455A (en) 2022-03-25
EP3125864A1 (en) 2017-02-08
US10016431B2 (en) 2018-07-10
JP7178731B2 (ja) 2022-11-28
US20170296543A1 (en) 2017-10-19
IL248090B (en) 2019-10-31
CL2016002463A1 (es) 2017-01-27
US20230355630A1 (en) 2023-11-09
US9895372B2 (en) 2018-02-20
BR112016020101A2 (es) 2017-07-15
RS54973B1 (sr) 2016-11-30
PH12016501519B1 (en) 2017-02-06
US20210137927A1 (en) 2021-05-13
EP2926805B1 (en) 2016-05-18
AU2015239736A1 (en) 2016-08-11
JP2021105062A (ja) 2021-07-26
KR102374500B1 (ko) 2022-03-15
US20170112836A1 (en) 2017-04-27
HUE030221T2 (en) 2017-04-28
JP2019194227A (ja) 2019-11-07
US20220031703A9 (en) 2022-02-03
HRP20160802T1 (hr) 2016-08-12
PL2926805T3 (pl) 2016-12-30
CY1117881T1 (el) 2018-03-07
US20180289714A1 (en) 2018-10-11
ZA201605271B (en) 2017-08-30
CN106572976A (zh) 2017-04-19
CA2938267A1 (en) 2015-10-08
PE20161253A1 (es) 2016-11-13
MY180844A (en) 2020-12-10
US10925877B2 (en) 2021-02-23
SI2926805T1 (sl) 2016-09-30
PH12016501519A1 (en) 2017-02-06
JP6552515B2 (ja) 2019-07-31
ES2586945T3 (es) 2016-10-19
SA516371933B1 (ar) 2019-04-14
DK2926805T3 (en) 2016-07-25
RU2016141449A3 (es) 2018-12-14
SMT201600246B (it) 2016-08-31
CN113521017A (zh) 2021-10-22
BR112016020101A8 (pt) 2021-06-29
HK1213195A1 (zh) 2016-06-30
KR20160138406A (ko) 2016-12-05

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2019009932A (es) Derivados de quinazolina usados para tratar el virus de inmunodeficiencia humana (vih).
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
PH12020550341A1 (en) Niraparib formulations
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2016001422A (es) Composicion farmaceutica de fingolimod.
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
PH12019500024A1 (en) Pharmaceutical compositions
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний